Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Research article

A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania

Edith AM Tarimo12*, Anna Thorson1, Thecla W Kohi2, Muhammad Bakari3, Eric Sandstrom5, Fred Mhalu4 and Asli Kulane1

Author Affiliations

1 Division of Global Health (IHCAR), Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden

2 Department of Nursing Management, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

3 Department of Internal Medicine Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

4 Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

5 Södersjukhuset, Venhalsan, Karolinska Institutet, Stockholm, Sweden

For all author emails, please log on.

BMC Infectious Diseases 2011, 11:283  doi:10.1186/1471-2334-11-283

Published: 24 October 2011

Abstract

Background

Evaluating experiences of volunteers in an HIV vaccine trial will be useful for the conduct of future trials. The purpose of this study among volunteers who participated in a phase I/II HIV vaccine trial in Dar es Salaam, Tanzania was to assess what characterized their experiences during the trial.

Methods

We conducted four focus group discussions with 35 out of the 60 individuals (women and men) after the five scheduled vaccinations. An interpretive description approach was applied to data analysis.

Results

As a result of the trial interventions, both men and women gained confidence in their own abilities to have safer, less risky sexual behaviour. The participants experienced the trial as a way of accessing free [insured] medical services. Most of the men said they had gone from self-medication to professional medical consultation. Despite these benefits, the participants faced various challenges during the trial. Such challenges included mistrust of the trial shown by health care providers who were not connected to the trial and discouragement from friends, colleagues and family members who questioned the safety of the trial. However, they managed to cope with these doubts by using both personal and trial related interventions.

Conclusion

We found that during the phase I/II HIV vaccine trial, participants had both the opportunities and the ability to cope with the doubts from the surrounding community. Follow up visits enhanced the opportunities and individuals' abilities to cope with the doubts during the trial. Understanding this discourse may be useful for the trial implementers when designing future trials.

Trials Registration

ISRCTN: ISRCTN90053831

Pan African Clinical Trials Registry (PACTR): ATMR2009040001075080